What is Spero Therapeutics?

Spero Therapeutics is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing novel treatments for bacterial infections, including multidrug resistant bacterial infections and rare diseases.

Will GSK buy Spero Therapeutics?

Sept 22 (Reuters) - British drugmaker GSK said on Thursday it would take a stake in Spero Therapeutics (SPRO.O) as part of a licensing agreement for the U.S.-based drug developer's experimental antibiotic for complicated urinary tract infections (cUTI).

What makes Spero unique?

Spero was founded to address the serious infections and the growing global threat of antibiotic resistance through innovative therapeutic approaches. Our ability to provide effective therapies today will have long-term impacts on patients’ lives. We’ve built an organization on foundations of stability, momentum and commitment to excellence.

Is Spero targeting a high unmet medical need?

Spero is targeting indications with both high unmet medical need and good commercialization opportunities. In addition to the lead compound SPR720, the pipeline includes two partnered programs, Tebipenem HBr and SPR206. Regarding Tebipenem HBr, the statements in my first article are still valid.